Home Overview Press Room Blog Publications For Students about us
Search

Biotech & Pharma : Displaying 11-20 of 2332


In science, follow the money – if you canby Paul D. Thacker & Curt FurbergThe Los Angeles TimesMay 12th, 2016Disclosure and restrictions do not harm academic freedom. These policies still allow scientists to pursue research, while ensuring that public health is not put at risk in service of corporate profit.
Three Cambridge startups are on a mission to fix broken genesby Robert WeismanThe Boston GlobeMay 11th, 2016Editas, Intellia & CRISPR Tx aim to cure diseases from cancer to blood disorders, but these would-be gene editors also must navigate a new round of ethical questions.
Indian woman gives birth at ~70 with help of IVFby Andrew MarszalThe Telegraph [UK]May 10th, 2016Post-menopausal births with donor eggs are increasingly common in India, where couples are often under intense social pressure to have children.
Gene Therapy’s First Out-and-Out Cure Is Hereby Antonio RegaladoMIT Technology ReviewMay 6th, 2016A genetic therapy treatment for severe combined immune deficiency, also known as "bubble boy" disease, is now pending approval in Europe.
The World’s Most Expensive Medicine Is a Bustby Antonio RegaladoMIT Technology ReviewMay 5th, 2016The first gene therapy approved in the Western world costs $1 million and has been used just once.
Hacking CRISPR: Patents, Gene Therapy & Embryosby Elliot HosmanMay 5th, 2016As gene editing experiments on human embryos spread, piecemeal hacks of CRISPR are outpacing discussions of the futures it might enable.
Google's DeepMind shouldn't suck up our NHS records in secretby Randeep RameshThe Guardian [US]May 4th, 2016The revelation that 1.6 million patients’ records are being used by the company’s artificial intelligence arm rings alarm bells.
Cultural Influences Reflected in Divergent US vs UK Human Embryo Research Policies[citing CGS' Marcy Darnovsky]by Eli Y. AdashiThe JAMA ForumMay 3rd, 2016Reactions to CRISPR gene editing experiments depend upon a country's existing laws and regulation.
Dead could be brought 'back to life' in groundbreaking projectby Sarah KnaptonThe Telegraph [UK]May 3rd, 2016A US biotech firm received permission to recruit 20 clinically dead patients for a stem cell treatment.
The gene editor CRISPR won’t fully fix sick people anytime soon. Here’s whyby Jocelyn KaiserScience/AAASMay 3rd, 2016After more than two decades of ups and downs, veterans of the gene therapy field are wary of raising expectations about CRISPR for treating diseases.
Displaying 11-20 of 2332  
< Prev  Next >> 
« First Page Last Page » 
« Show Complete List » 


ESPAÑOL | PORTUGUÊS | Русский

home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1122 University Ave, Suite 100, Berkeley, CA 94702 • • (p) 1.510.665.7760 • (F) 1.510.665.8760